<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Quetiapine - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../sickbay-shared.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Quetiapine</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../../index.html">Home</a>
        <a class="btn small" href="../../index.html#/sickbay-meds">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Neuro / Psych</div>
      <h1>Quetiapine</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Quetiapine 25mg Tablets</li>
          <li>Quetiapine 50mg Tablets</li>
          <li>Quetiapine 100mg Tablets</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <p><strong>IMPORTANT:</strong> Quetiapine initiation/dosing in acute settings should generally be done under psychiatric/medical direction. The following represents typical dosing ranges; adjust per specialist guidance.</p>
        <ul>
          <li><strong>Acute agitation/acute psychosis (short-term emergency use; medical direction strongly advised)</strong>
            <ul>
              <li>Typical starting dose: 25–50 mg PO; may repeat after 2–4 hours if needed and tolerated</li>
              <li>Do not exceed 400 mg/day in acute settings without specialist consultation</li>
            </ul>
          </li>
          <li><strong>Continuation of established therapy (patient already on quetiapine)</strong>
            <ul>
              <li>Continue home dose as prescribed (commonly 50–800 mg/day in divided doses or once daily depending on formulation and indication)</li>
              <li>Immediate-release: typically dosed 2–3 times daily; extended-release: once daily</li>
            </ul>
          </li>
          <li><strong>Schizophrenia/bipolar disorder (long-term management; specialist-directed)</strong>
            <ul>
              <li>Initial titration typically starts at 25–50 mg twice daily and increases gradually over several days to weeks</li>
              <li>Target dose varies by indication (schizophrenia: 150–750 mg/day; bipolar: varies widely)</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Schizophrenia (acute and maintenance treatment)</li>
          <li>Bipolar disorder (manic episodes, depressive episodes, maintenance therapy)</li>
          <li>Acute agitation in psychotic disorders (short-term emergency management)</li>
          <li>Continuation of established psychiatric therapy when patient is unable to access usual care</li>
          <li>Off-label uses (e.g., insomnia, anxiety) should be under specialist direction and are not recommended for acute onboard initiation</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>Known hypersensitivity to quetiapine</li>
          <li>Caution in elderly patients with dementia-related psychosis (increased risk of mortality; black box warning)</li>
          <li>Risk of neuroleptic malignant syndrome (NMS): fever, rigidity, altered mental status, autonomic instability—medical emergency</li>
          <li>Risk of tardive dyskinesia with prolonged use (involuntary movements)</li>
          <li>Metabolic effects: hyperglycemia, diabetes, weight gain, dyslipidemia (monitor in long-term use)</li>
          <li>Orthostatic hypotension (especially during initiation or dose increases; fall risk)</li>
          <li>QT prolongation: caution in patients with cardiac disease, electrolyte imbalances, or concurrent QT-prolonging medications</li>
          <li>Sedation/drowsiness: impairs ability to perform tasks requiring alertness (operating machinery, etc.)</li>
          <li>Hepatic impairment: dose reduction may be needed</li>
          <li>Pregnancy/breastfeeding: use only if benefit outweighs risk; consult specialist</li>
          <li>Abrupt discontinuation may cause withdrawal symptoms; taper when stopping</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>Sedation, drowsiness, fatigue (very common, especially initially)</li>
          <li>Orthostatic hypotension, dizziness, tachycardia</li>
          <li>Weight gain, increased appetite</li>
          <li>Hyperglycemia, new-onset diabetes or worsening of existing diabetes</li>
          <li>Dyslipidemia (elevated cholesterol/triglycerides)</li>
          <li>Anticholinergic effects: dry mouth, constipation, urinary retention, blurred vision</li>
          <li>Extrapyramidal symptoms (EPS): less common than with typical antipsychotics but possible (tremor, rigidity, akathisia)</li>
          <li>Neuroleptic malignant syndrome (rare but life-threatening)</li>
          <li>Tardive dyskinesia (risk increases with duration of use)</li>
          <li>QT prolongation, arrhythmias (rare)</li>
          <li>Increased prolactin (less common than with some other antipsychotics)</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li>May be taken with or without food</li>
          <li>Immediate-release tablets: can be divided if scored; typically dosed 2–3 times daily</li>
          <li>Extended-release formulation (if available): swallow whole; do not crush, chew, or split; dosed once daily</li>
          <li>Start at low dose and titrate slowly to minimize orthostatic hypotension and sedation</li>
          <li>Advise patient to rise slowly from sitting/lying to reduce dizziness/falls</li>
          <li>Do not stop abruptly; taper gradually under medical supervision to avoid withdrawal</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Mental status and psychiatric symptoms (efficacy and safety)</li>
          <li>Orthostatic vital signs (BP and HR lying and standing) especially after initiation or dose changes</li>
          <li>Sedation level and fall risk</li>
          <li>Blood glucose and HbA1c (baseline and periodically during long-term use)</li>
          <li>Lipid profile (baseline and periodically during long-term use)</li>
          <li>Weight and BMI (monitor for significant weight gain)</li>
          <li>Movement disorders (extrapyramidal symptoms, tardive dyskinesia) with ongoing assessment</li>
          <li>ECG if risk factors for QT prolongation or cardiac disease (baseline and as indicated)</li>
          <li>Signs of neuroleptic malignant syndrome (fever, rigidity, confusion, autonomic instability)—medical emergency</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>Initiation of quetiapine in acute settings should be done under psychiatric/medical consultation when possible</li>
          <li>Primarily useful for continuation of established home therapy in patients unable to access their usual medications</li>
          <li>For acute agitation/psychosis: use lowest effective dose; monitor closely for sedation, hypotension, and falls</li>
          <li>Ensure patient safety (fall precautions, supervision) given sedation and orthostatic hypotension risk</li>
          <li>Document baseline vital signs, mental status, and any changes during treatment</li>
          <li>Plan for psychiatric follow-up and specialist consultation as soon as feasible</li>
          <li>If NMS suspected (fever, rigidity, altered mental status), discontinue immediately and arrange urgent evacuation</li>
          <li>Limited lab monitoring capability at sea: prioritize clinical monitoring and early consultation for metabolic concerns</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (Quetiapine/Seroquel): <a href="https://pdf.hres.ca/dpd_pm/00067405.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00067405.PDF</a></li>
          <li>Canadian Psychiatric Association - Clinical Practice Guidelines: <a href="https://www.cpa-apc.org/publications/clinical-practice-guidelines/" target="_blank" rel="noopener">https://www.cpa-apc.org/publications/clinical-practice-guidelines/</a></li>
          <li>RxFiles - Antipsychotic comparison chart: <a href="https://www.rxfiles.ca/" target="_blank" rel="noopener">https://www.rxfiles.ca/</a></li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
